Leeds Osteoarthritis Hip Cohort

• Research type

  Research Study

• Full title

  Leeds Osteoarthritis Hip Cohort

• IRAS ID

  156919

• Contact name

  Philip Conaghan

• Contact email

  p.conaghan@leeds.ac.uk

• Sponsor organisation

  University of Leeds

• Duration of Study in the UK

  4 years, 0 months, 3 days

• Research summary

  Osteoarthritis (OA) affects approximately 10% of the UK population and is the fastest growing cause of disability. It affects an estimated 8.5 million people and accounts for more than one third of chronic moderate to severe pain in the UK. Globally, it is predicted to become the second and fourth leading cause of disability for women and men respectively.
  
  Hip OA itself is the second most common large joint affected by OA. The estimated worldwide mean prevalence of radiographic primary hip OA is 8.0%. Treatment options for hip OA remain limited, with no other proven therapy to halt the progression of disease except total hip replacement (THR). Drugs are used for symptom control only. In the UK, over 2.1 million people have sought treatment for OA in their hip, with over 80,000 hip replacements in 2011 in the UK due to OA. In 2010, the estimated cost of THR of the hip in the UK was £426million, which represented a 66% increase in costs over the past decade.

  An important process in developing disease modifying treatment would involve identifying and targeting early structural and clinical changes. Currently MRI assessment of the hip uses scoring systems of different features measured at multiple sites in the joint. However it is difficult for current assessment systems to demonstrate change over time, especially in a slowly evolving process like OA. Using modern image analysis of MRI will now enable us to study and produce more accurate hip OA classification and therefore direct treatment more appropriately.

  To date, there have been no MRI studies evaluating the development of hip OA , and examining features which predict the development and progression of clinical symptoms. This study, therefore, aims to establish such a cohort. Determining the prognosis for hip OA will be invaluable for primary prevention and therapeutic planning.

• REC name

  West Midlands - Coventry & Warwickshire Research Ethics Committee

• REC reference

  14/WM/1163

• Date of REC Opinion

  26 Sep 2014

• REC opinion

  Favourable Opinion